Reuters logo
BRIEF-Advaxis announces updated data at ASCO from phase 2 study of AXAL
2016年6月6日 / 上午11点22分 / 1 年前

BRIEF-Advaxis announces updated data at ASCO from phase 2 study of AXAL

June 6 (Reuters) - Advaxis Inc :

* Says results From Stage 1 Demonstrated A Twelve-Month survival rate of 38.5 percent

* Twelve-Month survival rate among 69 percent of patients who received maximum three per protocol doses was 56 percent

* Advaxis announces updated data at asco from a phase 2 study of axal in advanced cervical cancer showing promising survival rates consistent with earlier reports Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below